奥锐特(605116.SH)通过药品GMP符合性检查

Core Viewpoint - Aorite (605116.SH) has received the Drug GMP Compliance Inspection Notification from the Zhejiang Provincial Drug Administration, indicating that its production lines meet GMP requirements, which will help maintain product quality and production capacity [1] Group 1: GMP Compliance - The company passed the GMP compliance inspection for its raw materials, specifically Mometasone Furoate and Betamethasone, across designated workshops and production lines [1] - The inspection covered workshops 806, 863, and 802, as well as production lines A3 and BETB [1] Group 2: Impact on Operations - The successful GMP compliance will support the company's ability to meet market demand for its products [1] - The inspection results are not expected to have a significant impact on the company's financial performance [1]